BeOne Medicines (NASDAQ:ONC) SVP Chan Henry Lee Sells 590 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 590 shares of BeOne Medicines stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $265.98, for a total transaction of $156,928.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Chan Henry Lee also recently made the following trade(s):

• On Thursday, June 11th, Chan Henry Lee sold 428 shares of BeOne Medicines stock. The shares were sold at an average price of $257.63, for a total transaction of $110,265.64.
• On Monday, June 8th, Chan Henry Lee sold 871 shares of BeOne Medicines stock. The shares were sold at an average price of $270.42, for a total value of $235,535.82.
• On Wednesday, May 13th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The stock was sold at an average price of $310.72, for a total value of $103,159.04.
• On Wednesday, April 8th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The stock was sold at an average price of $311.59, for a total value of $103,447.88.

BeOne Medicines Trading Up 2.8%

Shares of ONC opened at $270.15 on Friday. The company has a market capitalization of $29.64 billion, a P/E ratio of 60.44 and a beta of 0.49. BeOne Medicines Ltd. – Sponsored ADR has a one year low of $239.25 and a one year high of $385.22. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64. The stock has a 50-day moving average price of $296.16 and a 200 day moving average price of $312.45.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The firm had revenue of $1.51 billion during the quarter. Sell-side analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Morgan Stanley reiterated an “overweight” rating and set a $395.00 price objective on shares of BeOne Medicines in a research note on Thursday, May 7th. Guggenheim upped their target price on shares of BeOne Medicines from $410.00 to $420.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Royal Bank Of Canada lifted their price target on BeOne Medicines from $425.00 to $436.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 2nd. Truist Financial reissued a “buy” rating and issued a $413.00 price objective (up from $411.00) on shares of BeOne Medicines in a report on Thursday, May 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of BeOne Medicines in a research note on Monday, April 20th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $390.00.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Capital International Investors raised its stake in BeOne Medicines by 1.3% during the fourth quarter. Capital International Investors now owns 5,113,866 shares of the company’s stock worth $1,553,909,000 after acquiring an additional 67,808 shares during the period. Siren L.L.C. boosted its stake in BeOne Medicines by 1.4% in the fourth quarter. Siren L.L.C. now owns 500,000 shares of the company’s stock valued at $151,905,000 after acquiring an additional 7,010 shares during the period. Morgan Stanley boosted its stake in BeOne Medicines by 23.9% in the fourth quarter. Morgan Stanley now owns 437,661 shares of the company’s stock valued at $132,966,000 after acquiring an additional 84,367 shares during the period. Bank of America Corp DE grew its holdings in shares of BeOne Medicines by 7.0% during the first quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock valued at $120,354,000 after purchasing an additional 26,441 shares during the last quarter. Finally, Candriam S.C.A. raised its position in shares of BeOne Medicines by 31.7% during the 1st quarter. Candriam S.C.A. now owns 259,731 shares of the company’s stock worth $77,132,000 after purchasing an additional 62,470 shares during the period. 48.55% of the stock is currently owned by institutional investors.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.